Amneal Pharmaceuticals (AMRX) Income from Continuing Operations (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted Income from Continuing Operations of $69.6 million for Q2 2026, down 10.75% on a QoQ basis from $78.0 million in Q1 2026, and up 95.49% year-over-year from $35.6 million in Q2 2025.
Amneal Pharmaceuticals (AMRX) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals has reported Income from Continuing Operations for 10 years, with the latest figure at $69.6 million in Q2 2026.
- On a quarterly basis, Income from Continuing Operations rose 95.49% year-over-year to $69.6 million in Q2 2026; TTM through Jun 2026 was $215.3 million, a 320.19% increase from a year earlier, with the FY2025 full-year figure at $127.9 million, up 273.17% from the prior year.
- Income from Continuing Operations was $69.6 million for Q2 2026 at Amneal Pharmaceuticals, down from $78.0 million in the prior quarter.
- The five-year high for Income from Continuing Operations was $78.0 million in Q1 2026, with the low at -$240.1 million in Q2 2022.
- Average Income from Continuing Operations over 5 years is -$5.7 million, with a median of $14.3 million recorded in 2024.
- The largest YoY upside for Income from Continuing Operations was 1135.41% in 2023 against a maximum downside of 1494.26% in 2023.
- Over 5 years, Income from Continuing Operations stood at -$5.9 million in 2022, then plunged by 1494.26% to -$93.3 million in 2023, then surged by 77.78% to -$20.7 million in 2024, then jumped by 339.0% to $49.6 million in 2025, then surged by 40.43% to $69.6 million in 2026.
- The last three Income from Continuing Operations figures came in at $69.6 million (Q2 2026), $78.0 million (Q1 2026), and $49.6 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 46.72 Bn | 43.07 Bn | 2.15 Bn | -576.00 Mn |
| 2 | Viatris | 19.64 Bn | 18.75 Bn | 1.46 Bn | -118.80 Mn |
| 3 | Dr Reddys Laboratories | 10.36 Bn | 10.22 Bn | 396.53 Mn | 45.93 Mn |
| 4 | Amneal Pharmaceuticals | 6.44 Bn | 6.39 Bn | 334.51 Mn | 69.61 Mn |
| 5 | Bausch Health Companies | 2.11 Bn | 1.24 Bn | 2.10 Bn | 260.00 Mn |
| 6 | Ani Pharmaceuticals | 1.88 Bn | 1.52 Bn | 165.89 Mn | 24.70 Mn |
| 7 | Alvotech | 1.83 Bn | 1.69 Bn | 2.56 Mn | -66.70 Mn |
| 8 | Amphastar Pharmaceuticals | 1.04 Bn | 751.07 Mn | 93.47 Mn | 30.35 Mn |
| 9 | Fennec Pharmaceuticals | 382.22 Mn | 340.97 Mn | 17.15 Mn | 1.97 Mn |
| 10 | NutriBand | 94.45 Mn | 91.03 Mn | 181,874.00 | -880,561.00 |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 69.61 Mn |
| Mar 31, 2026 | 78.00 Mn |
| Dec 31, 2025 | 49.57 Mn |
| Sep 30, 2025 | 18.13 Mn |
| Jun 30, 2025 | 35.61 Mn |
| Mar 31, 2025 | 24.62 Mn |
| Dec 31, 2024 | -20.74 Mn |
| Sep 30, 2024 | 11.76 Mn |
| Jun 30, 2024 | 16.79 Mn |
| Mar 31, 2024 | -81.68 Mn |
| Dec 31, 2023 | -93.34 Mn |
| Sep 30, 2023 | 25.06 Mn |
| Jun 30, 2023 | 29.68 Mn |
| Mar 31, 2023 | -10.13 Mn |
| Dec 31, 2022 | -5.86 Mn |
| Sep 30, 2022 | -2.42 Mn |
| Jun 30, 2022 | -240.13 Mn |
| Mar 31, 2022 | -6.42 Mn |
| Dec 31, 2021 | -20.42 Mn |
| Sep 30, 2021 | -6.09 Mn |
Amneal Pharmaceuticals Income from Continuing Operations API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=AMRX&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-continuing-operations", "ticker": "AMRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=income-from-continuing-operations&ticker=AMRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();